StreetInsider.com News Articles

Keymed Biosciences Announces 2025 Annual Results and Business Updates

Thu, 26 Mar 2026 09:54:00 -0400

BEIJING, March 26, 2026 /PRNewswire/ -- Keymed Biosciences (HKEX: 02162) announced its 2025 annual results. The year marked the company's 10th anniversary and a pivotal year in its transition from R&D to commercialization.

Revenue Leaps Forward, Supporting Long-Term Stable Growth

Since its founding in 2016, Keymed has built a pipeline of over 50 programs, with more than 10 in clinical development, three indications successfully launched, six core technology platforms continuously upgraded, over 10 external partnerships established, and planned production capacity exceeding 100,000 liters.

In terms of financial performance, the company achieved

Keymed Biosciences Announces 2025 Annual Results and Business Updates

Thu, 26 Mar 2026 09:54:00 -0400

Revenue Leaps Forward, Supporting Long-Term Stable Growth

In terms of financial performance, the company achieved

Keymed Biosciences Announces 2025 Annual Results and Business Updates

Thu, 26 Mar 2026 09:54:00 -0400

Revenue Leaps Forward, Supporting Long-Term Stable Growth

In terms of financial performance, the company achieved

Keymed Biosciences Announces 2025 Annual Results and Business Updates

Thu, 26 Mar 2026 09:54:00 -0400

Revenue Leaps Forward, Supporting Long-Term Stable Growth

In terms of financial performance, the company achieved

Keymed Biosciences Announces 2025 Annual Results and Business Updates

Thu, 26 Mar 2026 09:54:00 -0400

Revenue Leaps Forward, Supporting Long-Term Stable Growth

In terms of financial performance, the company achieved

Keymed Biosciences Announces 2025 Annual Results and Business Updates

Thu, 26 Mar 2026 09:54:00 -0400

Revenue Leaps Forward, Supporting Long-Term Stable Growth

In terms of financial performance, the company achieved

Keymed Biosciences Announces 2025 Annual Results and Business Updates

Thu, 26 Mar 2026 09:54:00 -0400

Revenue Leaps Forward, Supporting Long-Term Stable Growth

In terms of financial performance, the company achieved

Keymed Biosciences Announces 2025 Annual Results and Business Updates

Thu, 26 Mar 2026 09:54:00 -0400

Revenue Leaps Forward, Supporting Long-Term Stable Growth

In terms of financial performance, the company achieved

Keymed Biosciences Announces 2025 Annual Results and Business Updates

Thu, 26 Mar 2026 09:54:00 -0400

Revenue Leaps Forward, Supporting Long-Term Stable Growth

In terms of financial performance, the company achieved

Keymed Biosciences Announces 2025 Annual Results and Business Updates

Thu, 26 Mar 2026 09:54:00 -0400

Revenue Leaps Forward, Supporting Long-Term Stable Growth

In terms of financial performance, the company achieved

Keymed Biosciences Announces 2025 Annual Results and Business Updates

Thu, 26 Mar 2026 09:54:00 -0400

Revenue Leaps Forward, Supporting Long-Term Stable Growth

In terms of financial performance, the company achieved

Keymed Biosciences Announces 2025 Annual Results and Business Updates

Thu, 26 Mar 2026 09:54:00 -0400

Revenue Leaps Forward, Supporting Long-Term Stable Growth

In terms of financial performance, the company achieved

Keymed Biosciences Announces 2025 Annual Results and Business Updates

Thu, 26 Mar 2026 09:54:00 -0400

Revenue Leaps Forward, Supporting Long-Term Stable Growth

In terms of financial performance, the company achieved

Keymed Biosciences Announces 2025 Annual Results and Business Updates

Thu, 26 Mar 2026 09:54:00 -0400

Revenue Leaps Forward, Supporting Long-Term Stable Growth

In terms of financial performance, the company achieved

Keymed Biosciences Announces 2025 Annual Results and Business Updates

Thu, 26 Mar 2026 09:54:00 -0400

Revenue Leaps Forward, Supporting Long-Term Stable Growth

In terms of financial performance, the company achieved

Keymed Biosciences Announces 2025 Annual Results and Business Updates

Thu, 26 Mar 2026 09:54:00 -0400

Revenue Leaps Forward, Supporting Long-Term Stable Growth

In terms of financial performance, the company achieved

Keymed Biosciences Announces 2025 Annual Results and Business Updates

Thu, 26 Mar 2026 09:54:00 -0400

Revenue Leaps Forward, Supporting Long-Term Stable Growth

In terms of financial performance, the company achieved

Keymed Biosciences Announces 2025 Annual Results and Business Updates

Thu, 26 Mar 2026 09:54:00 -0400

Revenue Leaps Forward, Supporting Long-Term Stable Growth

In terms of financial performance, the company achieved

Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum

Wed, 27 Aug 2025 02:02:00 -0400

CHENGDU, China, Aug. 27, 2025 /PRNewswire/ -- Keymed Biosciences Inc. ("Keymed", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&D progress.

Financially, the company achieved record revenue, driven by the strong performance of its core product, Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®. The drug generated net sales of approximately RMB 170 million. Keymed strengthened its balance sheet with a successful placement raising ~HK$864 million, providing ample funds for pipeline development and commercialization.

The differentiated R&D pipeline advanced significantly. Key highlights include:

Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum

Wed, 27 Aug 2025 02:02:00 -0400

CHENGDU, China, Aug. 27, 2025 /PRNewswire/ -- Keymed Biosciences Inc. ("Keymed", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&D progress.

The differentiated R&D pipeline advanced significantly. Key highlights include:

Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum

Wed, 27 Aug 2025 02:02:00 -0400

CHENGDU, China, Aug. 27, 2025 /PRNewswire/ -- Keymed Biosciences Inc. ("Keymed", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&D progress.

The differentiated R&D pipeline advanced significantly. Key highlights include:

Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum

Wed, 27 Aug 2025 02:02:00 -0400

CHENGDU, China, Aug. 27, 2025 /PRNewswire/ -- Keymed Biosciences Inc. ("Keymed", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&D progress.

The differentiated R&D pipeline advanced significantly. Key highlights include:

Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum

Wed, 27 Aug 2025 02:02:00 -0400

CHENGDU, China, Aug. 27, 2025 /PRNewswire/ -- Keymed Biosciences Inc. ("Keymed", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&D progress.

The differentiated R&D pipeline advanced significantly. Key highlights include:

Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum

Wed, 27 Aug 2025 02:02:00 -0400

CHENGDU, China, Aug. 27, 2025 /PRNewswire/ -- Keymed Biosciences Inc. ("Keymed", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&D progress.

The differentiated R&D pipeline advanced significantly. Key highlights include:

Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum

Wed, 27 Aug 2025 02:02:00 -0400

CHENGDU, China, Aug. 27, 2025 /PRNewswire/ -- Keymed Biosciences Inc. ("Keymed", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&D progress.

The differentiated R&D pipeline advanced significantly. Key highlights include: